---
title: "Humana's Solid Q1 Earnings Beat Tempered by Reduced Guidance"
description: "Humana reported strong Q1 earnings, beating estimates for both revenue and earnings. The company's strategic growth initiatives, including expansion into the CenterWell segment, contributed to its suc"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/202936318.md"
published_at: "2024-04-26T14:51:14.000Z"
---

# Humana's Solid Q1 Earnings Beat Tempered by Reduced Guidance

> Humana reported strong Q1 earnings, beating estimates for both revenue and earnings. The company's strategic growth initiatives, including expansion into the CenterWell segment, contributed to its success. However, Humana reduced its full-year guidance for GAAP EPS, reflecting caution in navigating operational and market challenges. Investors should focus on member growth in Medicare Advantage programs, Medicaid expansion, and developments in the CenterWell segment.

Health insurance giant **Humana** (HUM -0.89%) released its first-quarter earnings for 2024 on Wednesday, dazzling investors and analysts alike. It not only beat analysts' estimates for both earnings and revenue but also showcased its ongoing strategic growth endeavors.

Metrics

Q1 2024

Analyst Estimates

Q1 2023

Change (YOY)

Revenue

$29.6 billion

$28.5 billion

$26.7 billion

10.7%

Adjusted EPS

$7.23

$6.12

$9.38

\-22.9%

GAAP EPS

$6.11

N/A

$9.87

\-38.1%

Operating expenses

$28.4 billion

N/A

$25 billion

+13.4%

Operating cost ratio

10.4%

N/A

11.2%

+80 bps

Analyst source: FactSet. YOY = Year over year. BPS = Basis points. GAAP = Generally accepted accounting principles.

## Humana's profile and strategic focus

Humana stands at the forefront of the health insurance industry, with its core focus on the Medicare Advantage program. This program constitutes a significant portion of Humana's revenue. Through comprehensive health insurance benefits, Humana caters to Medicare-eligible individuals, blending wellness programs, chronic care management, and care coordination under one roof.

Moreover, Humana's strategic expansion into the CenterWell segment marks its ambition beyond traditional insurance. CenterWell encompasses pharmacy solutions, primary care, and home solutions, aiming for innovation in healthcare services and operational efficiencies.

## Quarterly highlights

This quarter saw Humana's adjusted EPS climb to $7.23, primarily driven by higher-than-expected revenue and operational efficiencies. The company's revenue surged to $29.6 billion, attributed to robust performance in its insurance segment and strategic expansions in Medicaid across multiple states.

Besides financial performance, Humana reported a significant increase in its growth estimate for individual Medicare Advantage membership. It revised its annual growth expectation to 150,000, an increase of 50,000 over the previous outlook. That would be a 2.8% increase over 2023 totals. This upward adjustment highlights Humana's successful strategy in attracting and retaining members in this critical segment.

Additionally, Humana's focus on the CenterWell segment brought about promising developments. CenterWell quarterly revenue of $4.82 billion was up 6.9% year over year. From expanding home solutions to enhancing primary care offerings, these strategic moves aim to diversify Humana's revenue streams and solidify its footprint in the healthcare services market.

The quarter was not without its challenges, as the company saw total operating expenses of $28.4 billion, up 13.4% year over year. The increase was attributed to higher overall benefits expenses and operating costs. The operating cost ratio, however, improved by 80 basis points year over year to 14.6%, thanks to rising scale and cost efficiencies.

## Looking ahead

For the remainder of 2024, Humana has adjusted its full-year GAAP EPS guidance to approximately $13.93, a decrease from its initial forecast of $14.87. However, it maintains an optimistic view on the adjusted EPS, holding steadfast at $16. This outlook reflects Humana's cautious yet hopeful perspective on navigating operational and market challenges ahead.

Investors should monitor Humana's efforts in member growth within its Medicare Advantage programs, its expansion into Medicaid, and further developments in the CenterWell segment. These areas, combined with Humana's adaptability to changing healthcare landscapes, will be crucial for its continuing success.

### Related Stocks

- [HUM.US - Humana](https://longbridge.com/en/quote/HUM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 休曼納｜10-K：2025 財年營收 1287 億美元不及預期 |  | [Link](https://longbridge.com/en/news/276370855.md) |
| 休曼納公司 SEC 10-K 年度報告 | Humana Inc. 發佈了其 2025 年的 10-K 表格報告，強調總收入增長 10.1%，達到 1297 億美元，主要受 Medicare 保險費增長的推動。淨收入略微下降 0.9%，為 12 億美元。該公司通過保險和 Center | [Link](https://longbridge.com/en/news/276371705.md) |
| 張德熙料金價未來兩季挑戰 6000 美元 港金所夥阿里開發交易平台 | 香港黃金交易所舉行新春開市儀式，金價為 46,518 元，預計未來兩季將挑戰每盎士 6,000 美元。張德熙表示，金價在牛市初中期，若發生美伊戰爭將小幅調整後再上升。交易所與阿里巴巴合作開發國際貴金屬交易平台，提供多種交易服務，並計劃推出  | [Link](https://longbridge.com/en/news/276406795.md) |
| 貝森特和沃什的 “導師”，德魯肯米勒 Q4“精準” 開倉金融股 ETF、標普等權重 ETF 和巴西 ETF | 科技股方面，德魯肯米勒 Q4 清倉了 Meta，加倉了谷歌與 Sea。德魯肯米勒與貝森特、沃什的 “師徒” 關係讓市場推測，“德魯肯米勒經濟學”——即反赤字、反通脹、反關税——可能通過貝森特和沃什滲透至政策制定中。 | [Link](https://longbridge.com/en/news/276214511.md) |
| 安德森斯｜10-K：2025 財年營收 110 億美元不及預期 |  | [Link](https://longbridge.com/en/news/276269991.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.